GlassScriptPhysician profile
Christine Urbanski
NPI 1548201528
$5,488.22
in general payments reported to CMS, 2019-2025
58 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.65 · 2021: $745 · 2022: $1,087 · 2023: $1,069 · 2024: $1,515 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,473 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,472.76 |
| Education | $168.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $624.26 | 2021-2025 | Kisqali |
| Astrazeneca Pharmaceuticals LP | $425.27 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Incyte Corporation | $348.01 | 2021-2024 | Jakafi, Monjuvi |
| Janssen Biotech, INC. | $311.70 | 2021-2025 | Talvey, Tecvayli, Imbruvica |
| Daiichi Sankyo INC. | $237.66 | 2021-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $217.64 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $210.03 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $197.17 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $194.51 | 2021-2025 | Fruzaqla, Ninlaro |
| Celgene Corporation | $136.86 | 2022-2024 | Reblozyl |
| Amgen INC. | $128.01 | 2021-2023 | Lumakras |
| Eisai INC. | $124.69 | 2021-2025 | |
| Genzyme Corporation | $121.50 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.51 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $106.26 | 2023-2025 | Onivyde, Somatuline Depot |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $101.60 | 2022-2025 | Provenge |
| Regeneron Healthcare Solutions, INC. | $100.40 | 2023-2025 | Libtayo |
| Beigene USA, INC. | $96.12 | 2022-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $95.89 | 2022-2023 | Imbruvica, Epkinly |
| Seagen INC. | $88.49 | 2022-2023 | Adcetris, Tukysa |
| Abbvie INC. | $81.10 | 2024-2025 | |
| Mirati Therapeutics, INC. | $73.39 | 2023 | Krazati |
| Sumitomo Pharma America, INC. | $70.97 | 2023-2024 | Orgovyx |
| Genentech USA, INC. | $68.07 | 2022-2025 | Venclexta, Itovebi |
| Tersera Therapeutics LLC | $67.08 | 2023-2025 | Zoladex, Xermelo |
| Array Biopharma INC | $62.31 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Taiho Oncology, INC. | $61.13 | 2021-2025 | |
| Astellas Pharma US INC | $60.32 | 2023-2025 | Padcev, Xospata |
| Janssen Pharmaceuticals, INC | $57.36 | 2021-2024 | Xarelto |
| Lilly USA, LLC | $51.22 | 2024-2025 | Jaypirca, Verzenio |
| Gilead Sciences, INC. | $50.61 | 2021-2023 | Trodelvy |
| Adc Therapeutics America, INC. | $48.87 | 2023-2024 | |
| Sobi, INC | $48.54 | 2025 | |
| Glaxosmithkline, LLC. | $46.59 | 2023-2025 | Ojjaara |
| Karyopharm Therapeutics INC. | $43.74 | 2021-2024 | Xpovio |
| Recordati_rare_diseases_inc. | $43.68 | 2025 | Enjaymo |
| Servier Pharmaceuticals LLC | $41.36 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $39.24 | 2021-2024 | Myrisk |
| G1 Therapeutics, INC. | $37.34 | 2022 | |
| Emd Serono, INC. | $36.73 | 2021-2023 | Bavencio |
| Deciphera Pharmaceuticals INC. | $36.06 | 2022-2024 | Qinlock |
| Pharmaessentia USA Corporation | $35.16 | 2023-2024 | Besremi |
| Kite Pharma, INC. | $33.76 | 2023 | Yescarta |
| Medtronic, INC. | $33.19 | 2024 | Illumisite |
| Tempus Ai, INC | $31.51 | 2024 | Xt Cdx |
| Aveo Pharmaceuticals, INC. | $24.27 | 2022 | |
| Genmab U.S., INC. | $23.97 | 2021 | |
| Blueprint Medicines Corporation | $22.77 | 2021 | |
| Puma Biotechnology, INC. | $21.74 | 2024 | |
| Dova Pharmaceuticals | $20.96 | 2021 | |
| Cti Biopharma Corp. | $19.70 | 2022 | |
| Pharmacosmos Therapeutics INC. | $19.66 | 2025 | Monoferric |
| Beone Medicines USA, INC. | $18.91 | 2025 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.74 | 2025 | |
| Agios Pharmaceuticals, INC. | $17.70 | 2022 | |
| Clovis Oncology, INC. | $14.74 | 2022 | |
| Apellis Pharmaceuticals, INC. | $14.09 | 2022 | |
| Pharming Healthcare, INC. | $13.06 | 2023 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Urbanski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.